Cannabis and Fatty Liver: Risks and UK Advice

Cannabis and fatty liver disease is a topic attracting growing scientific interest, yet the evidence remains complex and often misunderstood. Fatty liver disease affects up to one in three adults in the UK, and many people who use cannabis wonder whether it helps, harms, or has no meaningful effect on their liver health. This article examines what the current research shows, explores the biological mechanisms involved, outlines the specific risks for people with existing liver disease, and sets out the evidence-based lifestyle changes recommended by NHS and NICE guidance for managing fatty liver disease.

What is fatty liver disease and how does it develop?

Fatty liver disease occurs when excess fat accumulates in liver cells, most commonly driven by obesity, insulin resistance, and poor diet. NICE guidance (NG49) recommends FIB-4 or NAFLD fibrosis scoring as the first-line risk stratification tool in primary care.

Fatty liver disease occurs when excess fat accumulates within liver cells, impairing normal liver function over time. It is broadly divided into two main types: metabolic dysfunction-associated steatotic liver disease (MASLD, previously called non-alcoholic fatty liver disease or NAFLD) and alcohol-related liver disease (ALD). MASLD is now the most common chronic liver condition in the UK; the British Liver Trust estimates that up to one in three adults in the UK has some degree of fatty liver, though the exact figure varies by population studied.^[1][17]

The liver plays a central role in fat metabolism, processing dietary fats and producing lipoproteins that transport fat around the body. When this balance is disrupted, triglycerides accumulate within hepatocytes (liver cells). Key drivers include:

• Obesity and excess visceral fat, particularly around the abdomen

• Type 2 diabetes and insulin resistance, which promote fat storage in the liver

• High intake of refined carbohydrates and ultra-processed foods

• Sedentary behaviour and low levels of physical activity

• Excessive alcohol consumption, which directly damages liver cells

• Other metabolic risk factors such as dyslipidaemia, obstructive sleep apnoea, and polycystic ovary syndrome

In many people, fatty liver remains at a simple steatosis stage and causes no symptoms. However, in a proportion of individuals, the condition progresses to metabolic dysfunction-associated steatohepatitis (MASH, previously called non-alcoholic steatohepatitis or NASH), where inflammation and liver cell injury occur alongside fat accumulation. Without intervention, this can advance to fibrosis (scarring), cirrhosis, and in some cases liver failure or hepatocellular carcinoma.

NICE guidance (NG49) sets out a clear primary care pathway for adults with risk factors such as obesity or type 2 diabetes. The recommended first step is a non-invasive fibrosis risk score, either the FIB-4 index or the NAFLD fibrosis score, using age-specific cut-offs to identify those at low, indeterminate, or high risk of significant fibrosis. Where the result is indeterminate, NICE recommends the Enhanced Liver Fibrosis (ELF) blood test (NICE DG34) as a second-line assessment. Liver ultrasound is used to detect steatosis or to exclude other pathology, but it is not a sensitive tool for staging fibrosis and is not the primary means of risk stratification. People identified as high risk of significant fibrosis should be referred to hepatology for further assessment.

If you experience any of the following symptoms, seek urgent medical attention: vomiting blood or passing black, tarry stools (call 999 or go to A&E immediately); rapidly worsening jaundice (yellowing of the skin or eyes); severe confusion or drowsiness; or new or rapidly increasing abdominal swelling. For concerns that are urgent but not immediately life-threatening, contact your GP or call NHS 111.

Can cannabis use affect your liver health?

Cannabis interacts with CB1 and CB2 receptors in the liver, which may influence fat synthesis and inflammation, but the overall effect on human liver health depends on pattern of use and individual health status. People with liver disease should seek medical advice before using any CBD product.

Cannabis use can affect liver health, though the nature and direction of that effect remain an active area of scientific debate. Cannabis contains hundreds of bioactive compounds, the most studied being delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). These compounds interact with the endocannabinoid system, which includes receptors found throughout the body, including in the liver. The two primary receptor types, CB1 and CB2, have distinct roles in hepatic (liver) function.

CB1 receptor activation in the liver has been associated in preclinical and animal studies with increased fat synthesis (lipogenesis) and reduced fat breakdown, processes that could theoretically promote fat accumulation in liver cells.^[4][5] CB2 receptors, by contrast, appear to have anti-inflammatory properties and may play a protective role in liver inflammation.^[7] It is important to note that most of this mechanistic evidence comes from animal or cell-based research, and its direct relevance to human liver disease remains uncertain. The overall effect of cannabis on the human liver is not straightforward and may depend on the pattern of use, the compounds involved, and the individual's underlying health status.

The route of cannabis administration also matters. Smoking cannabis introduces combustion products that carry their own cardiovascular and respiratory risks; NHS Stop Smoking services can provide support for those who wish to stop. Oral or vaporised forms have different absorption profiles. CBD-only products, which are widely available in the UK as food supplements, are regulated by the Food Standards Agency (FSA) as novel foods and are not the same as cannabis-based products for medicinal use (CBPMs).^[8][9] CBPMs are controlled drugs that can only be initiated by a specialist clinician, in line with NICE guidance (NG144). The FSA advises healthy adults to consume no more than 10 mg of CBD per day from food supplements; people with liver disease should seek medical advice before using any CBD product, as there are specific concerns about liver and thyroid effects at higher doses. If you use cannabis regularly and have concerns about your liver health, speaking to your GP is the appropriate first step.

What does the current research say about cannabis and fatty liver?

Current research is mixed; some large observational studies report lower fatty liver prevalence in cannabis users, but these findings cannot prove causation and no UK clinical guideline recommends cannabinoids as a treatment for fatty liver disease.

Current research on cannabis and fatty liver presents a genuinely mixed picture, with some studies suggesting a protective association and others pointing to potential harm. Several large observational studies, including analyses of US national health survey data (such as the National Health and Nutrition Examination Survey, NHANES), have found that regular cannabis users have a lower prevalence of NAFLD (now termed MASLD) compared with non-users, even after adjusting for body mass index and alcohol use.^[11] Researchers have proposed that CB2 receptor activation may reduce hepatic inflammation, and that cannabis users may have altered metabolic profiles that influence fat storage. However, systematic reviews of this evidence highlight substantial heterogeneity between studies and significant methodological limitations.

These findings must be interpreted with considerable caution for several reasons:

• Observational studies cannot prove causation. People who use cannabis may differ from non-users in many ways that affect liver health, including diet, activity levels, and other substance use.

• Self-reported cannabis use is unreliable, making it difficult to accurately quantify dose and frequency.

• Heavy or dependent cannabis use has been associated in some studies with a higher risk of liver fibrosis, particularly in people who already have chronic liver disease such as hepatitis C.^[12][13]

• Some prescription-grade CBD products (such as high-dose cannabidiol used in clinical trials) have been associated with elevated liver enzymes (transaminases) in randomised controlled trials; self-medicating with high-dose CBD products is therefore not advisable.^[15]

• Synthetic cannabinoids (sometimes called “spice”) have been linked to acute liver injury in case reports, though these are chemically distinct from plant-derived cannabis and carry separate risks.

At present, no UK clinical guideline from NICE, NHS England, or the British Society of Gastroenterology recommends cannabis or cannabinoid compounds as a treatment for fatty liver disease. The evidence base is preliminary and largely derived from observational data. Robust, prospective clinical trials in humans are needed before any firm conclusions can be drawn about therapeutic potential.

Are there any risks of using cannabis if you already have liver disease?

People with established liver disease face specific risks from cannabis, including worsened hepatic encephalopathy, altered cannabinoid metabolism, and clinically significant drug interactions with warfarin and immunosuppressants via CYP3A4 and CYP2C9 enzymes.

People who already have established liver disease face specific risks from cannabis use that healthy individuals may not. The liver is responsible for metabolising many substances, including cannabinoids, and when liver function is impaired, this process is less efficient. In people with cirrhosis or advanced fibrosis, the metabolism of THC and other cannabinoids may be significantly altered, leading to unpredictable effects and potentially prolonged drug action.

Several specific concerns are worth highlighting:

• Hepatic encephalopathy: Cannabis use, particularly heavy use, may worsen cognitive symptoms in people with cirrhosis who are at risk of hepatic encephalopathy, a condition where toxins accumulate in the blood and affect brain function.

• Drug interactions: Cannabinoids are metabolised by cytochrome P450 enzymes (including CYP3A4 and CYP2C9) in the liver. This means cannabis and CBD can interact with medications commonly used in liver disease management. Examples include warfarin (CBD may raise INR, increasing bleeding risk) and immunosuppressants such as tacrolimus or ciclosporin used after liver transplantation (cannabinoids may alter drug levels via CYP3A4). Always check interactions using the BNF or with your pharmacist or GP before starting any cannabis or CBD product alongside prescribed medicines.

• Cannabinoid hyperemesis syndrome (CHS): Heavy, long-term cannabis use can cause CHS, characterised by cyclical vomiting and abdominal pain, which can be difficult to distinguish from other liver-related symptoms and may delay appropriate diagnosis.

• Alcohol co-use: Cannabis and alcohol are frequently used together, and their combined effect on the liver is likely to be more harmful than either alone.

If you have a diagnosed liver condition and use cannabis, it is important to inform your hepatologist or GP. Seek emergency care (call 999 or go to A&E) if you experience vomiting blood, passing black or tarry stools, severe confusion or drowsiness, rapidly worsening jaundice, or sudden severe abdominal swelling. For urgent but non-emergency concerns, contact your GP or call NHS 111. Suspected adverse reactions to any medicine or substance can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What lifestyle changes can help manage fatty liver in the UK?

Lifestyle modification is the primary evidence-based treatment for fatty liver disease in the UK, with gradual weight loss of 7 to 10 per cent of body weight, a Mediterranean-style diet, and at least 150 minutes of moderate aerobic activity per week being the most impactful changes.

Lifestyle modification remains the most evidence-based approach to managing fatty liver disease in the UK, and for many people it can halt or even reverse early-stage disease. NICE guidance (NG49) and NHS clinical pathways consistently emphasise that no pharmacological treatment is currently licensed specifically for MASLD in the general UK population, making behavioural change the cornerstone of management.^[21][22] (This position should be verified against current MHRA licences and NICE guidance at the time of reading, as the licensing landscape may change.)

The most impactful lifestyle changes include:

• Gradual, sustained weight loss: Losing 7 to 10 per cent of body weight has been shown in clinical studies to significantly reduce liver fat and inflammation, and greater losses may improve fibrosis.^[17] Crash dieting is not recommended, as rapid weight loss can paradoxically worsen liver inflammation.

• Dietary adjustment: A Mediterranean-style diet, rich in vegetables, legumes, whole grains, fish, and olive oil, is associated with reduced liver fat. Limiting added sugars, particularly fructose from sugary drinks and ultra-processed foods, is especially important.

• Regular physical activity: Both aerobic exercise (such as brisk walking or cycling) and resistance training have been shown to reduce liver fat independently of weight loss. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, plus muscle-strengthening activities on at least two days per week, and reducing prolonged sedentary time.^[18][19]

• Alcohol reduction or abstinence: Even in MASLD, alcohol can accelerate liver damage. The UK Chief Medical Officers' Low Risk Drinking Guidelines recommend consuming no more than 14 units of alcohol per week, spread across three or more days, with several alcohol-free days each week.^[20] Your clinician may advise complete abstinence depending on the severity of your liver disease.

• Avoiding unnecessary supplements: Some herbal supplements and high-dose CBD products can themselves be hepatotoxic. The FSA advises healthy adults to take no more than 10 mg of CBD per day from food supplements; people with liver disease should be especially cautious and should discuss any supplements, including CBD, with their GP or pharmacist before use.

For people who are overweight or obese, referral to a structured weight management programme through the NHS may be appropriate, subject to local Integrated Care Board (ICB) commissioning and clinical eligibility criteria. In some cases, a GP may discuss whether medicines to support weight management are clinically suitable. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of options may be considered based on individual clinical need. Regular monitoring through your GP, including liver function blood tests, remains essential for anyone with a confirmed diagnosis of fatty liver disease.

Scientific References

1. Liver disease: applying All Our Health.
2. Metabolic dysfunction-associated steatotic liver disease (NG49).
3. MRI-based technologies for assessing non-alcoholic fatty liver disease – Chapter 2: The diagnostic tests (HTG65).
4. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
5. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver.
6. Cannabinoids provoke alcoholic steatosis through a conspiracy of neighbors.
7. Cannabidiol as a Modulator of the Gut-Liver Axis: Clinical and Pharmacological Insights into Hepatic and Metabolic Disorder Therapies.
8. Cannabidiol (CBD).
9. CBD novel food applications: recommendations to ministers on first authorisations.
10. Cannabis-based medicinal products (NG144).
11. A Systematic Review and Meta-Analysis of Cannabis Use Frequency and Metabolic Dysfunction-Associated Steatotic Liver Disease: Scapegoat or Healer?.
12. Use of cannabis and risk of advanced liver fibrosis in patients with chronic hepatitis C virus infection: A systematic review and meta-analysis.
13. Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort.
14. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort).
15. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults.
16. Sativex Oromucosal Spray – Summary of Product Characteristics.
17. Non-alcoholic fatty liver disease (NAFLD).
18. Physical activity guidelines: UK Chief Medical Officers' report.
19. Physical activity guidelines for adults aged 19 to 64.
20. Alcohol consumption: advice on low risk drinking.
21. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
22. Draft scope post-referral: treatment of MASLD/MASH (GID-TA11477).

Frequently Asked Questions